Focal Interest
Focal Interest

Clinical endpoint

  1. Olutasidenib showed disease control in IDH1-mutated chondrosarcoma
    Phase 1b/2 trial of olutasidenib in IDH1-mutated chondrosarcoma shows disease control without dose-limiting toxicities; 52% stable disease rate in recurrent/metastatic disease.
  2. FMT with immunotherapy showed activity in NSCLC and melanoma
    Phase 2 trial: donor FMT plus first-line ICI in NSCLC and melanoma showed high ORRs and implicates loss of specific bacterial taxa in association with response.